- Market Capitalization, $K 13,685,127
- Shares Outstanding, K 1,092,189
- Annual Sales, $ 16,887 M
- Annual Income, $ -998,000 K
- 60-Month Beta 1.60
- Price/Sales 0.84
- Price/Cash Flow 3.32
- Price/Book 0.97
|Period||Period Low||Period High||Performance|
| || |
+1.46 (+13.19%)since 04/29/20
| || |
+1.00 (+8.67%)since 02/28/20
| || |
+2.83 (+29.18%)since 05/29/19
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...
, /PRNewswire/ -- The Global Pulmonary Drug Delivery Devices Market is expected to grow from in 2018 to by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.31%. Read the full report: The...
, /PRNewswire/ --
The global asthma treatment market size is expected to reach USD 26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period. The growing incidence of respiratory diseases such of chronic...
, /PRNewswire/ -- The report has been added to offering.
MarketResearch.Biz published a new industry research report “Acute Kidney Injury Treatment Market” in its database. This is a latest report, including the present COVID-19 impact and future effect on...
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) ("Teva"), announced today that, in the interest of the health and safety of its shareholders, directors, officers and employees in light of...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented a wide range of important new data on AJOVY(R) (fremanezumab) and the societal and economic impact of migraine in Europe at the 6th Congress...
Though Teva (TEVA) faces several challenges, with encouraging progress on restructuring activities and stabilization in the generics business, it may return to growth in 2020 or 2021.
--GALA open-label extension study evaluates 7-year efficacy and safety results of COPAXONE